Eupraxia Pharmaceuticals Inc.

NASDAQ:EPRX

Biotechnology

Healthcare
$6.21 +1.11%

+$0.07 today

Market cap
$417.57M
Beta
1.48
P/E (TTM)
-8.5
EPS (TTM)
-$0.74
52W Low $4.19High $9.32

Volume 1.21M

Average 0.22M

Income Statement

Follow revenue through to earnings.

Revenue

$0.00

FY 2025 · Annual

Operating Income

-$53.66M

FY 2025 · Annual

Net Income

-$53.86M

FY 2025 · Annual

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CAD
FY2022
Dec 2022 · CAD
FY2023
Dec 2023 · USD
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Revenue00000
Cost of Revenue112.38K00163.47K331.89K
Gross Profit(112.38K)00(163.47K)(331.89K)
Gross Margin—————
Research & Development7.59M13.63M15.33M16.07M29.51M
Selling, General & Admin6.97M3.99M5.63M10.92M17.1M
Operating Expenses14.65M17.62M20.97M26.99M53.33M
Depreciation & Amortization87.47K147.89K117.1K171.6K331.89K
EBITDA(17.22M)(17.86M)(20.78M)(24.95M)(53.33M)
EBITDA Margin—————
Operating Income(14.65M)(17.62M)(20.97M)(26.99M)(53.66M)
Operating Margin—————
Interest Income51.55K431.8K649.75K1.16M1.41M
Interest Expense1.02M982.86K881.05K603.17K0
Other Income / Expenses(3.68M)(1.37M)(814.93K)1.26M(212.94K)
Income Before Tax(18.33M)(18.99M)(21.78M)(25.73M)(53.87M)
Pre-Tax Margin—————
Income Tax Expense0027.42K1.8K26.65K
Net Income(18.03M)(18.49M)(21.25M)(25.49M)(53.86M)
Net Margin—————
EPS (Basic)(1.63)(0.96)(0.88)(0.76)(1.05)
EPS (Diluted)(1.63)(0.96)(0.88)(0.76)(1.05)
Weighted Avg Shares14.24M19.29M24.15M33.93M39.96M
Weighted Avg Shares (Diluted)14.24M19.29M24.15M33.93M39.96M

EPRX Earnings Waterfall · TTM

NASDAQ:EPRX · Revenue to Net Income

Key Ratios

EPS$-1.00
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-7.7
P/S Ratio0.0

Analysis

$0 of revenue converted into -$42.5M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.00, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
S-8S-8 filingNov 12, 2026
6-K6-K filingNov 10, 2026
6-K6-K filingNov 10, 2026
6-K6-K filingNov 10, 2026
6-K6-K filingNov 10, 2026

How much revenue does EPRX generate?

Eupraxia Pharmaceuticals Inc. (EPRX) reported $0.00 of revenue in fiscal 2025.

Is EPRX profitable?

Eupraxia Pharmaceuticals Inc. (EPRX) reported -$53.86M of net income.